Safety Monitoring of Gender-Affirming Hormone Therapy in Transgender Men

doi:10.12280/gjszjk.20230329

Abstract

Abstract:

Gender-affirming hormone therapy (GAHT) is the inevitable and most important way for transgender people to undergo gender transition, while the safety of hormone therapy needs more attention. For transgender men, the use of androgen (male hormone) will undoubtedly affect their physiological indicators, and even lead to some adverse reactions. For transgender men, intramuscular injection of testosterone undecanoate (TU) 1 000 mg every 12 weeks is currently the mainstream GAHT program in the world, with the best safety, effectiveness, economy and convenience. The GAHT of transgender men should be monitored for hematocrit, liver function, blood lipids, blood pressure, lean body mass, body mass index, bone mineral density, etc., to avoid the possible adverse events caused by excess androgen. This paper reviewed the GAHT of transgender men and its safety monitoring, and provided a reference for safe and rational use of GAHT for Chinese transgender men.

Key words: Transgender men, Gender-affirming hormone therapy, Testosterone, Safety monitoring, Therapy

SU Ling, CAI Wei-yao, HE Jia-xin, GAO Lyu-fen. Safety Monitoring of Gender-Affirming Hormone Therapy in Transgender Men[J]. Journal of International Reproductive Health/Family Planning, 2023, 42(6): 476-480.

Figures/Tables 1

References 20

[1]	Winter S, Diamond M, Green J, et al. Transgender people: health at the margins of society[J]. Lancet, 2016, 388(10042):390-400. doi: 10.1016/S0140-6736(16)00683-8. pmid: 27323925
[2]	Moral-Martos A, Guerrero-Femández J, GÓmez-Balaguer M, et al. Clinical practice guidelines for transsexual, transgender and gender diverse minors[J]. An Pediatr (Engl Ed), 2022, 96(4):349.e1-349.e11. doi: 10.1016/j.anpede.2022.02.002.
[3]	Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8[J]. Int J Transgend Health, 2022, 23(Suppl 1):S1-S259. doi: 10.1080/26895269.2022.2100644.
[4]	T′Sjoen G, Arcelus J, De Vries ALC, et al. European Society for Sexual Medicine Position Statement "Assessment and Hormonal Management in Adolescent and Adult Trans People, With Attention for Sexual Function and Satisfaction"[J]. J Sex Med, 2020, 17(4):570-584. doi: 10.1016/j.jsxm.2020.01.012.
[5]	Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2017, 102(11):3869-3903. doi: 10.1210/jc.2017-01658. pmid: 28945902
[6]	Oh JW, Yun Y, Lee ES. A Review of Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults in South Korea[J]. J Menopausal Med, 2022, 28(3):92-102. doi: 10.6118/jmm.22039.
[7]	Nolan BJ, Leemaqz SY, Ooi O, et al. Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals[J]. Intern Med J, 2021, 51(6):873-878. doi: 10.1111/imj.14839.
[8]	Madsen MC, van Dijk D, Wiepjes CM, et al. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years[J]. J Clin Endocrinol Metab, 2021, 106(6):1710-1717. doi: 10.1210/clinem/dgab089. pmid: 33599731
[9]	Stangl TA, Wiepjes CM, Defreyne J, et al. Is there a need for liver enzyme monitoring in people using gender-affirming hormone therapy?[J]. Eur J Endocrinol, 2021, 184(4):513-520. doi: 10.1530/EJE-20-1064. pmid: 33524005
[10]	Hashemi L, Zhang Q, Getahun D, et al. Longitudinal Changes in Liver Enzyme Levels Among Transgender People Receiving Gender Affirming Hormone Therapy[J]. J Sex Med, 2021, 18(9):1662-1675. doi: 10.1016/j.jsxm.2021.06.011.
[11]	Boekhout-Berends ET, Wiepjes CM, Nota NM, et al. Changes in laboratory results in transgender individuals on hormone therapy - a retrospective study and practical approach[J]. Eur J Endocrinol, 2023, 188(5):457-466. doi: 10.1093/ejendo/lvad052.
[12]	Millington K, Chan YM. Lipoprotein subtypes after testosterone therapy in transmasculine adolescents[J]. J Clin Lipidol, 2021, 15(6):840-844. doi: 10.1016/j.jacl.2021.09.051. pmid: 34657833
[13]	Carlotta C, Giovanni C, Davide I, et al. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI)[J]. J Sex Med, 2021, 18(4):821-829. doi: 10.1016/j.jsxm.2021.01.185.
[14]	Pyra M, Casimiro I, Rusie L, et al. An Observational Study of Hypertension and Thromboembolism Among Transgender Patients Using Gender-Affirming Hormone Therapy[J]. Transgend Health, 2020, 5(1):1-9. doi: 10.1089/trgh.2019.0061. pmid: 32322683
[15]	Banks K, Kyinn M, Leemaqz SY, et al. Blood Pressure Effects of Gender-Affirming Hormone Therapy in Transgender and Gender-Diverse Adults[J]. Hypertension, 2021, 77(6):2066-2074. doi: 10.1161/HYPERTENSIONAHA.120.16839.
[16]	Wiik A, Lundberg TR, Rullman E, et al. Muscle Strength, Size, and Composition Following 12 Months of Gender-affirming Treatment in Transgender Individuals[J]. J Clin Endocrinol Metab, 2020, 105(3):dgz247. doi: 10.1210/clinem/dgz247.
[17]	Bretherton I, Spanos C, Leemaqz SY, et al. Insulin resistance in transgender individuals correlates with android fat mass[J]. Ther Adv Endocrinol Metab, 2021, 12:2042018820985681. doi: 10.1177/2042018820985681.
[18]	Valentine A, Nokoff N, Bonny A, et al. Cardiometabolic Parameters Among Transgender Adolescent Males on Testosterone Therapy and Body Mass Index-Matched Cisgender Females[J]. Transgend Health, 2021, 6(6):369-373. doi: 10.1089/trgh.2020.0052. pmid: 34993308
[19]	Stoffers IE, de Vries MC, Hannema SE. Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria[J]. J Sex Med, 2019, 16(9):1459-1468. doi: 10.1016/j.jsxm.2019.06.014.
[20]	Lee JY, Finlayson C, Olson-Kennedy J, et al. Low Bone Mineral Density in Early Pubertal Transgender/Gender Diverse Youth: Findings From the Trans Youth Care Study[J]. J Endocr Soc, 2020, 4(9):bvaa065. doi: 10.1210/jendso/bvaa065.

剂型	药品名称	优缺点	指南推荐方案
剂型	药品名称	优缺点	世界跨性别健康专业协会（WPATH）	欧洲性医学学会科学委员会（ESSM）	美国内分泌协会（ENDO）	韩国
注射制剂	庚酸睾酮注射剂	优点：疗效好、便宜；缺点：注射部位不适、血清睾酮水平容易波动、红细胞增多症风险大	每2周100~200 mg肌内注射或每周50~100 mg皮下注射	每2~3周200~250 mg肌内注射或每周75~125 mg皮下注射	每2周100~200 mg肌内注射或每周50~100 mg皮下注射	每2周100~200 mg肌内注射，或每3~4周250 mg肌内注射，或每周50~100 mg皮下注射
	环丙酸睾酮注射剂	优点：疗效好、抑制月经方面效果好、血清睾酮水平比较平稳；缺点：注射疼痛较大、红细胞增多症风险大	每2周100~200 mg肌内注射或每周50~100 mg皮下注射	每2~3周200~250 mg肌内注射或每周75~125 mg皮下注射	每2周100~200 mg肌内注射或每周50~100 mg皮下注射	每2周100~200 mg肌内注射，或每3~4周250 mg肌内注射，或每周50~100 mg皮下注射
	十一酸睾酮注射剂	优点：长效、疗效好、便宜；缺点：注射部位不适、红细胞增多症风险大	每12周1 000 mg肌内注射或每10周750 mg肌内注射	每10~12周1 000 mg肌内注射或每周75~125 mg皮下注射	每12周1 000 mg肌内注射	每12周1 000 mg肌内注射
透皮制剂	睾酮凝胶	优点：方便、剂量随时调整、红细胞增多症风险小；肝毒性小；缺点：经皮肤传递给他人、皮肤敏感者出现红斑、贵	1.6%：50~100 mg/d	25~100 mg/d	1.6%：50~100 mg/d	2.0%：30~80 mg/d
	睾酮鼻凝胶	-	-	-	-	22~33 mg/d
	睾酮透皮贴剂	优点：方便、剂量随时调整、红细胞增多症风险小、肝毒性小；缺点：皮肤过敏、瘙痒、不适感、贵	2.5~7.5 mg/d	-	2.5~7.5 mg/d	-
口服制剂	十一酸睾酮软胶囊	优点：方便、剂量随时调整；缺点：吸收差、容易漏服	每天1~2次口服，总剂量160 mg	每天1~2次口服，总剂量160 mg	-	-

剂型	药品名称	优缺点	指南推荐方案
剂型	药品名称	优缺点	世界跨性别健康专业协会（WPATH）	欧洲性医学学会科学委员会（ESSM）	美国内分泌协会（ENDO）	韩国
注射制剂	庚酸睾酮注射剂	优点：疗效好、便宜；缺点：注射部位不适、血清睾酮水平容易波动、红细胞增多症风险大	每2周100~200 mg肌内注射或每周50~100 mg皮下注射	每2~3周200~250 mg肌内注射或每周75~125 mg皮下注射	每2周100~200 mg肌内注射或每周50~100 mg皮下注射	每2周100~200 mg肌内注射，或每3~4周250 mg肌内注射，或每周50~100 mg皮下注射
	环丙酸睾酮注射剂	优点：疗效好、抑制月经方面效果好、血清睾酮水平比较平稳；缺点：注射疼痛较大、红细胞增多症风险大	每2周100~200 mg肌内注射或每周50~100 mg皮下注射	每2~3周200~250 mg肌内注射或每周75~125 mg皮下注射	每2周100~200 mg肌内注射或每周50~100 mg皮下注射	每2周100~200 mg肌内注射，或每3~4周250 mg肌内注射，或每周50~100 mg皮下注射
	十一酸睾酮注射剂	优点：长效、疗效好、便宜；缺点：注射部位不适、红细胞增多症风险大	每12周1 000 mg肌内注射或每10周750 mg肌内注射	每10~12周1 000 mg肌内注射或每周75~125 mg皮下注射	每12周1 000 mg肌内注射	每12周1 000 mg肌内注射
透皮制剂	睾酮凝胶	优点：方便、剂量随时调整、红细胞增多症风险小；肝毒性小；缺点：经皮肤传递给他人、皮肤敏感者出现红斑、贵	1.6%：50~100 mg/d	25~100 mg/d	1.6%：50~100 mg/d	2.0%：30~80 mg/d
	睾酮鼻凝胶	-	-	-	-	22~33 mg/d
	睾酮透皮贴剂	优点：方便、剂量随时调整、红细胞增多症风险小、肝毒性小；缺点：皮肤过敏、瘙痒、不适感、贵	2.5~7.5 mg/d	-	2.5~7.5 mg/d	-
口服制剂	十一酸睾酮软胶囊	优点：方便、剂量随时调整；缺点：吸收差、容易漏服	每天1~2次口服，总剂量160 mg	每天1~2次口服，总剂量160 mg	-	-